Literature DB >> 28523515

Distribution of Exogenous and Endogenous CYP3A Markers and Related Factors in Healthy Males and Females.

Jieon Lee1, Andrew HyoungJin Kim1, SoJeong Yi1, SeungHwan Lee1, Seo Hyun Yoon1, Kyung-Sang Yu1, In-Jin Jang1, Joo-Youn Cho2.   

Abstract

Cytochrome P450 (CYP) 3A is an important drug-metabolizing enzyme in humans. Assessing CYP3A activity is necessary for predicting therapeutic outcomes or the potential adverse events of various therapeutics. This study sought to evaluate the distribution of endogenous and exogenous markers reflecting hepatic CYP3A activity and related factors affecting its activity in healthy male and female. Each subject was given a single 1 mg dose of midazolam intravenously. Pharmacokinetics, pharmacometabolomics, and pharmacogenomics analyses were performed to evaluate CYP3A activity. Urinary and plasma steroids were quantified with gas chromatography coupled with triple-quadrupole mass spectrometry (GC-MS), and the concentrations of midazolam and its metabolites were quantified with liquid chromatography coupled with electrospray tandem mass spectrometry (LC-MS/MS). A total of 100 subjects completed this study. Midazolam clearance (MDZ CL) and the metabolic ratio (MDZ MR) were significantly correlated with 6β-OH-cortisol/cortisol and 6β-OH-cortisone/cortisone. MDZ CL, 6β-OH-cortisol/cortisol, and 6β-OH-cortisone/cortisone decreased with increasing age (Pearson r = -0.333, -0.329, and -0.528, respectively; P < 0.05). When the markers were compared according to sex, MDZ CL and 6β-OH-cortisol/cortisol showed significant difference between sexes. However, MDZ CL was higher in female group than male group and 6β-OH-cortisol/cortisol was higher in male group than female group. No significant differences in markers were found when comparing progesterone levels. Our results indicate that both exogenous and endogenous markers showed decreased CYP3A activity with increasing age, which suggested that age could be a factor that significantly influences CYP3A activity.

Entities:  

Keywords:  CYP3A; biomarkers; endogenous metabolites; midazolam; pharmacometabolomics

Mesh:

Substances:

Year:  2017        PMID: 28523515     DOI: 10.1208/s12248-017-0090-8

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  33 in total

1.  Aspirin decreases systemic exposure to clopidogrel through modulation of P-glycoprotein but does not alter its antithrombotic activity.

Authors:  J Oh; D Shin; K S Lim; S Lee; K-H Jung; K Chu; K S Hong; K-H Shin; J-Y Cho; S H Yoon; S C Ji; K-S Yu; H Lee; I-J Jang
Journal:  Clin Pharmacol Ther       Date:  2014-02-24       Impact factor: 6.875

2.  A highly sensitive LC-MS-MS assay for analysis of midazolam and its major metabolite in human plasma: applications to drug metabolism.

Authors:  Valquiria A P Jabor; Eduardo B Coelho; Neife A G Dos Santos; Pierina S Bonato; Vera L Lanchote
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2005-08-05       Impact factor: 3.205

3.  CYP3A4 intronic SNP rs35599367 (CYP3A4*22) alters RNA splicing.

Authors:  Danxin Wang; Wolfgang Sadee
Journal:  Pharmacogenet Genomics       Date:  2016-01       Impact factor: 2.089

4.  Reasons for calibration standard curve slope variation in LC-MS assays and how to address it.

Authors:  Yue Zhao; Guowen Liu; Jim X Shen; Anne-Francoise Aubry
Journal:  Bioanalysis       Date:  2014-06       Impact factor: 2.681

5.  4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.

Authors:  Anne-Joy M de Graan; Alex Sparreboom; Peter de Bruijn; Evert de Jonge; Bronno van der Holt; Erik A C Wiemer; Jaap Verweij; Ron H J Mathijssen; Ron H N van Schaik
Journal:  Br J Clin Pharmacol       Date:  2015-08-12       Impact factor: 4.335

6.  Menstrual cycle variability in midazolam pharmacokinetics.

Authors:  E D Kharasch; D Mautz; T Senn; G Lentz; K Cox
Journal:  J Clin Pharmacol       Date:  1999-03       Impact factor: 3.126

7.  A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach.

Authors:  Franc Andreu; Helena Colom; Laure Elens; Teun van Gelder; Ronald H N van Schaik; Dennis A Hesselink; Oriol Bestard; Joan Torras; Josep M Cruzado; Josep M Grinyó; Nuria Lloberas
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

Review 8.  Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.

Authors:  Ulrich M Zanger; Matthias Schwab
Journal:  Pharmacol Ther       Date:  2013-01-16       Impact factor: 12.310

9.  4β-Hydroxycholesterol as an endogenous biomarker of CYP3A activity in cynomolgus monkeys.

Authors:  Ke Li; Sylvia Zhao; Lingling Zhang; Xiaoyun Wu; Pan Shu; Yang Wang; Hao Feng; Zheming Gu; Helen Han Hsu
Journal:  Drug Metab Dispos       Date:  2014-03-04       Impact factor: 3.922

10.  Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin.

Authors:  Catherine Dutreix; Sebastien Lorenzo; Yanfeng Wang
Journal:  Eur J Clin Pharmacol       Date:  2014-05-21       Impact factor: 2.953

View more
  5 in total

Review 1.  Phenotyping of Human CYP450 Enzymes by Endobiotics: Current Knowledge and Methodological Approaches.

Authors:  Gaëlle Magliocco; Aurélien Thomas; Jules Desmeules; Youssef Daali
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

2.  The roles of cytochrome P450 and P-glycoprotein in the pharmacokinetics of florfenicol in chickens.

Authors:  G Y Wang; H H Zheng; K Y Zhang; F Yang; T Kong; B Zhou; Sh X Jiang
Journal:  Iran J Vet Res       Date:  2018       Impact factor: 1.376

3.  Studies on CYP3A activity during the menstrual cycle as measured by urinary 6β-hydroxycortisol/cortisol.

Authors:  Helena Bergström; Anna Lindahl; Anna Warnqvist; Ulf Diczfalusy; Lena Ekström; Linda Björkhem-Bergman
Journal:  Pharmacol Res Perspect       Date:  2021-12

4.  Assessment of Oral Vancomycin-Induced Alterations in Gut Bacterial Microbiota and Metabolome of Healthy Men.

Authors:  Andrew HyoungJin Kim; Yujin Lee; Eunwoo Kim; Sang Chun Ji; Jae-Yong Chung; Joo-Youn Cho
Journal:  Front Cell Infect Microbiol       Date:  2021-05-27       Impact factor: 5.293

5.  Assessment of Hepatic Cytochrome P450 3A Activity Using Metabolic Markers in Patients with Renal Impairment.

Authors:  Andrew HyoungJin Kim; Sumin Yoon; Yujin Lee; Jieon Lee; Eunjin Bae; Hajeong Lee; Dong Ki Kim; SeungHwan Lee; Kyung-Sang Yu; In-Jin Jang; Joo-Youn Cho
Journal:  J Korean Med Sci       Date:  2018-10-31       Impact factor: 2.153

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.